According to the Zhitong Finance App, TATA Health (01255) issued an announcement about the company's wholly-owned subsidiary, Shangying, entering into investment and shareholder agreements with co-investors, co-lenders, Promethera Biosciences and Promethera Therapeutics. According to this, Shangying will subscribe for new shares, which is equivalent to 37.61% of the total issued share capital of Promethera Therapeutics immediately after the investment and shareholder agreement is delivered.

According to the announcement, it was agreed in principle to extend the final deadline until August 27, 2021.